Stock Events

Stock Events

DBV Technologies 

$4.26
113
+$0+0% Friday 13:30

Statistics

Day High
4.26
Day Low
4.26
52W High
4.8
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.44
-0.3
-0.16
-0.02
Expected EPS
-0.02146036672
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-228.25MNet Income

Analyst Ratings

48.5Average Price Target
The highest estimate is 55.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DBVTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, involved in developing treatments for allergies and inflammatory diseases, competing in the broader allergy treatment market.
Sanofi
SNY
Mkt Cap110.4B
Sanofi, a large pharmaceutical company with a focus on immunology and allergy treatments, including collaborations on therapies that could compete with DBV's offerings.
Novavax
NVAX
Mkt Cap1.32B
Novavax, works on vaccines that could potentially address allergies, indirectly competing by targeting the underlying causes of allergic reactions.
Moderna
MRNA
Mkt Cap17.99B
Moderna, known for mRNA technology, which could be applied to develop vaccines or treatments for allergies, potentially competing with DBV's approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical, focuses on rare diseases but has interests in developing treatments that could overlap with allergy and immunotherapy markets.
Adma Biologics
ADMA
Mkt Cap2.44B
ADMA Biologics, specializes in immune globulin products which could be used in treating allergies, offering an alternative to DBV's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals, while primarily focused on cystic fibrosis, its research into other areas of medicine could lead to competitive treatments in the allergy space.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline, a large pharmaceutical company with a diverse portfolio, including respiratory and allergy treatments, potentially competing across several areas of DBV's interest.

About

There is no Profile data available for DBV.SG.
Show more...
CEO
Mr. Daniel Tassé
Country
France
ISIN
FR0010417345

Listings

MU
DE
DBV.MU
F
DE
DBV1.F
STU
DE
DBV1.STU
STU
DE
DBV.STU

0 Comments

Share your thoughts

FAQ

What is DBV Technologies stock price today?▼
The current price of DBVTF is $4.26 USD — it has increased by +0% in the past 24 hours. Watch DBV Technologies stock price performance more closely on the chart.
What is DBV Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange DBV Technologies stocks are traded under the ticker DBVTF.
When is the next DBV Technologies earnings date?▼
DBV Technologies is going to release the next earnings report on August 03, 2026.
What were DBV Technologies earnings last quarter?▼
DBVTF earnings for the last quarter are -0.02 USD per share, whereas the estimation was -0.03 USD resulting in a +19.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is DBV Technologies revenue for the last year?▼
DBV Technologies revenue for the last year amounts to 0 USD.
What is DBV Technologies net income for the last year?▼
DBVTF net income for the last year is -228.25M USD.
In which sector is DBV Technologies located?▼
DBV Technologies operates in the Other sector.
When did DBV Technologies complete a stock split?▼
The last stock split for DBV Technologies was on June 07, 2024 with a ratio of 1:2.
Where is DBV Technologies headquartered?▼
DBV Technologies is headquartered in Châtillon, France.